PBAC's latest decision on Pazopanib: Recommended (2013). Considered for Initial and continuing treatment of advanced (unresectable and/or metastatic) soft tissue sarcoma in patients who have received prior chemotherapy including anthracycline and have WHO performance status of 2 or less.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
$75k/QALY
$45k/QALY–$75k/QALY · across 2 submissions
Submissions
4
first 2010
Submissions
4
2010 → 2013
Eligible population
Adults with advanced (unresectable and/or metastatic) soft tissue sarcoma who have received prior chemotherapy including anthracycline, with WHO performance status 0–2, and no prior angiogenesis inhibitor treatment.
Therapy area
Oncology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
PFS
Pivotal trial size
369 patients
Key trials
VEG110727 (PALETTE), Van Oosterom 2002
Comparator
50% best supportive care and 50% ifosfamide/MESNA
Economic model
CUA
ICER basis
Range aggregates 2 submissions (2012–2013) — not a single base case.
Submission history
Jul 2010: Not recommended
2012: Not recommended · Authority Required — ICER $75k/QALY
Mar 2012: Recommended with restriction · Authority Required